|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Groeneweg JW, Foster R, Growdon WB,
Verheijen RH and Rueda BR: Notch signaling in serous ovarian
cancer. J Ovarian Res. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kathawala RJ, Gupta P, Ashby CR Jr and
Chen ZS: The modulation of ABC transporter-mediated multidrug
resistance in cancer: A review of the past decade. Drug Resist
Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tuorkey MJ: Curcumin a potent cancer
preventive agent: Mechanisms of cancer cell killing. Interv Med
Appl Sci. 6:139–146. 2014.PubMed/NCBI
|
|
6
|
Han X, DU F, Jiang L, Zhu Y, Chen Z, Liu
Y, Hong T, Wang T, Mao Y, Wu X, et al: A2780 human ovarian cancer
cells with acquired paclitaxel resistance display cancer stem cell
properties. Oncol Lett. 6:1295–1298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan L, Wang C, Lin B, Liu J, Liu D, Hou R,
Wang Y, Gao L, Zhang S and Iwamori M: Lewis y enhances CAM-DR in
ovarian cancer cells by activating the FAK signaling pathway and
upregulating Bcl-2/Bcl-XL expression. Biochimie. 113:17–25. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Marco R, Tolomelli A, Juaristi E and
Gentilucci L: Integrin ligands with α/β-hybrid peptide structure:
Design, bioactivity, and conformational aspects. Med Res Rev.
36:389–424. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blandin AF, Renner G, Lehmann M,
Lelong-Rebel I, Martin S and Dontenwill M: β1 Integrins as
therapeutic targets to disrupt hallmarks of cancer. Front
Pharmacol. 6:2792015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burkhalter RJ, Symowicz J, Hudson LG,
Gottardi CJ and Stack MS: Integrin regulation of beta-catenin
signaling in ovarian carcinoma. J Biol Chem. 286:23467–23475. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elliott T and Sethi T: Integrins and
extracellular matrix: A novel mechanism of multidrug resistance.
Expert Rev Anticancer Ther. 2:449–459. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamakawa N, Kaneda K, Saito Y, Ichihara E
and Morishita K: The increased expression of integrin α6 (ITGA6)
enhances drug resistance in EVI1(high) leukemia. PLoS One.
7:e307062012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brooks DL, Schwab LP, Krutilina R, Parke
DN, Sethuraman A, Hoogewijs D, Schörg A, Gotwald L, Fan M, Wenger
RH and Seagroves TN: ITGA6 is directly regulated by
hypoxia-inducible factors and enriches for cancer stem cell
activity and invasion in metastatic breast cancer models. Mol
Cancer. 15:262016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin F, Liu L, Liu X, Li G, Zheng L, Li D,
Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene
ribonuclease T2 and gametogenetin binding protein 2 is associated
with drug resistance in ovarian cancer. Oncol Rep. 32:362–372.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prat J: FIGO staging for uterine sarcomas.
Int J Gynaecol Obstet. 104:177–178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luvero D, Milani A and Ledermann JA:
Treatment options in recurrent ovarian cancer: Latest evidence and
clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia Y, Zeng ZZ, Markwart SM, Rockwood KF,
Ignatoski KM, Ethier SP and Livant DL: Integrin fibronectin
receptors in matrix metalloproteinase-1-dependent invasion by
breast cancer and mammary epithelial cells. Cancer Res.
64:8674–8681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dransfield I, Cabanas C, Barrett J and
Hogg N: Interaction of leukocyte integrins with ligand is necessary
but not sufficient for function. J Cell Biol. 116:1527–1535. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Janouskova H, Ray AM, Noulet F,
Lelong-Rebel I, Choulier L, Schaffner F, Lehmann M, Martin S,
Teisinger J and Dontenwill M: Activation of p53 pathway by
Nutlin-3a inhibits the expression of the therapeutic target alpha5
integrin in colon cancer cells. Cancer Lett. 336:307–318. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toquet C, Colson A, Jarry A, Bezieau S,
Volteau C, Boisseau P, Merlin D, Laboisse CL and Mosnier JF: ADAM15
to α5β1 integrin switch in colon carcinoma cells: A late event in
cancer progression associated with tumor dedifferentiation and poor
prognosis. Int J Cancer. 130:278–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maubant S, Cruet-Hennequart S, Poulain L,
Carreiras F, Sichel F, Luis J, Staedel C and Gauduchon P: Altered
adhesion properties and alphav integrin expression in a
cisplatin-resistant human ovarian carcinoma cell line. Int J
Cancer. 97:186–194. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HI, Huang H, Cheepala S, Huang S and
Chung J: Curcumin inhibition of integrin (alpha6beta4)-dependent
breast cancer cell motility and invasion. Cancer Prev Res (Phila).
1:385–391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Linhares MM, Affonso RJ Jr, Viana Lde S,
Silva SR, Denadai MV, de Toledo SR and Matos D: Genetic and
immunohistochemical expression of integrins ITGAV, ITGA6, and ITGA3
As prognostic factor for colorectal cancer: Models for global and
disease-free survival. PLoS One. 10:e01443332015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marthick JR and Dickinson JL: Emerging
putative biomarkers: The role of alpha 2 and 6 integrins in
susceptibility, treatment, and prognosis. Prostate Cancer.
2012:2987322012. View Article : Google Scholar : PubMed/NCBI
|
